GLPG 2451

Drug Profile

GLPG 2451

Alternative Names: GLPG2451

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer Galapagos NV
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 20 Jun 2017 Galapagos plans a triple combination therapy comprising GLPG 2451, GLPG 2222 and GLPG 2737 for Cystic fibrosis in the fourth quarter of 2017
  • 27 Apr 2017 Galapagos NV completes a phase I trial in Healthy volunteers (Combination therapy) in Belgium (PO) (NCT02788721)
  • 09 May 2016 Phase-I clinical trials in Cystic fibrosis (In volunteers, Monotherapy) in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top